Prescient's PTX-100 receives US FDA Fast Track Designation

April 16, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma. …

Subscribe now to continue reading.

Latest Video

Challenging headlines are the natural consequence of disrupting a very stale debate
April 15, 2025 - Latest News
Medicines Australia appoints new senior policy executive
April 15, 2025 - Latest News
This could be a path forward, a move to delay, or both, and we've seen it before
April 14, 2025 - Latest News
US FDA announces plan to phase-out animal testing in drug development
April 15, 2025 - Latest News
Sorry minister, but there's no world in which you kept this election commitment to newborns
April 14, 2025 - Latest News

Prescient's PTX-100 receives US FDA Fast Track Designation

This is a preview of subscriber content

Latest Video

Most Read

Challenging headlines are the natural consequence of disrupting a very stale debate

Medicines Australia appoints new senior policy executive

This could be a path forward, a move to delay, or both, and we've seen it before

US FDA announces plan to phase-out animal testing in drug development

Sorry minister, but there's no world in which you kept this election commitment to newborns

New Stories

Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate

Prescient's PTX-100 receives US FDA Fast Track Designation

Australian research finds turning off protein may help prevent liver cancer

UQ tests vaccine response in ‘moonshot’ challenge

Cartherics announces board changes, including a new chair

UCB welcomes new TGA registration for monoclonal antibody

Investors appear comfortable as Trump administration says pharma tariffs coming

Sign In

Prescient's PTX-100 receives US FDA Fast Track Designation

This is a preview of subscriber content

Latest Video

Most Read

Challenging headlines are the natural consequence of disrupting a very stale debate

Medicines Australia appoints new senior policy executive

This could be a path forward, a move to delay, or both, and we've seen it before

US FDA announces plan to phase-out animal testing in drug development

Sorry minister, but there's no world in which you kept this election commitment to newborns

Follow Us

New Stories

Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate

Prescient's PTX-100 receives US FDA Fast Track Designation

Australian research finds turning off protein may help prevent liver cancer

UQ tests vaccine response in ‘moonshot’ challenge

Cartherics announces board changes, including a new chair

UCB welcomes new TGA registration for monoclonal antibody

Investors appear comfortable as Trump administration says pharma tariffs coming